Summary of the Conference Call on the Pharmaceutical Industry Industry Overview - The pharmaceutical industry experienced a profit decline in 2019 due to centralized procurement policies, but demand growth during the pandemic provided some relief. By the first half of 2025, segments such as innovative drugs, pharmaceutical commerce, and CXO showed positive growth, although overall profit levels continued to decline [1][2]. Key Insights and Arguments - **Centralized Procurement Impact**: The centralized procurement of medical consumables began in 2020, leading to negative revenue growth for two consecutive quarters by Q4 2023. However, Q1 2024 saw a return to positive revenue growth, indicating a stabilization in high-value consumables [3][4]. - **Sector Performance**: The chemical preparations sector saw significant revenue declines in Q3 and Q4 of 2023, directly linked to centralized procurement policies. The medical consumables sector has faced revenue and profit pressures since 2022, with in vitro diagnostics (IVD) expected to face challenges starting Q4 2024 [5][6]. - **Future Outlook**: The worst period for the pharmaceutical industry is believed to be over, with price issues being resolved. The price levels are relatively low compared to international markets, and a return to positive growth is anticipated in Q2 2025, potentially leading to an overall positive growth for the year [6][7]. Segment-Specific Insights - **CXO Sector**: The CXO sector is divided into demand-driven and supply-driven enterprises. The latter has benefited from the recovery of overseas markets, while domestic demand-driven companies are beginning to show signs of recovery, as evidenced by the performance of companies like Tigermed and Northstar [7][8]. - **IVD Sector**: The IVD sector is under significant pressure due to policy impacts, with a notable 20% decline in Roche's domestic luminescence business. The overall industry growth rate is approximately -15% [12][13]. - **Medical Equipment**: The medical equipment sector has faced continuous declines since Q4 2023, but signs of recovery were noted in the first half of 2025, with companies like United Imaging and Mindray showing varying degrees of recovery [17][18]. Additional Important Points - **High-Value Consumables**: The high-value consumables sector has undergone multiple rounds of centralized procurement, leading to stable or improved performance for many companies. The gross margin levels for high-value consumables have reached a bottom, with certain products like artificial crystals beginning to see the effects of procurement policies [19][20]. - **Internationalization of Domestic Companies**: Domestic high-value consumables companies are enhancing their international capabilities, with significant clinical data published and FDA certifications obtained for products aimed at the U.S. market [23]. - **Market Competition**: The competition in the luminescence industry is intense, particularly among companies outside the top three, which are resorting to price cuts to gain market share, resulting in significant declines in gross margins [13][14]. This summary encapsulates the key points discussed in the conference call regarding the pharmaceutical industry, highlighting the challenges and opportunities within various segments.

Group 1: Company Performance - In the first half of 2025, the company achieved a revenue of 5.34 billion yuan, representing a year-on-year growth of 14.75% [3] - The net profit attributable to shareholders reached 25.38 million yuan, with a significant year-on-year increase of 140.35% [3] - The company's gross margin has improved significantly, indicating a fundamental enhancement in its financial health [3] Group 2: Strategic Planning - The company is focusing on a "one-stop service platform" for drug development, promoting a full-package service model to reduce communication costs and enhance efficiency [3] - The integration of AI technology into drug research and development is a key strategy, with successful applications in multiple core business areas [3] - The company aims to leverage its technological service capabilities to fill critical gaps in the industry chain and foster collaborative ecosystems [3] Group 3: Market Expansion - Over 80% of the company's revenue comes from overseas clients, with approximately 20% from the Asia-Pacific region [4] - The company is actively expanding its presence in the Asia-Pacific market and enhancing its service capabilities in Europe and the US [4] - New modality drug business has seen a significant increase, with orders from XDC and peptides rising from 8% to 17% year-on-year [5] Group 4: Customer Strategy - The company aims to secure long-term contracts with multinational corporations (MNCs) while also empowering more biotech firms as long-tail customers [5] - The customer structure is primarily composed of small to medium biotech firms, with a trend of MNC clients returning [5] - The company is focusing on enhancing collaboration with MNCs to stabilize its customer base and performance [5] Group 5: Financial Goals and Milestones - The long-term strategic goal is to capture 1% of the global CXO market, which is valued at 1 trillion USD [7] - The company targets a revenue increase to 2.5 billion yuan and a net profit of no less than 200 million yuan by 2027 [7] - Key milestones for the upcoming year include enhancing full-package services, establishing laboratories in Boston and the UK, and improving overall service capabilities [8]

Core Viewpoint - The recent adjustments to the Hang Seng Innovation Drug Index and the Hang Seng Hong Kong Stock Connect Innovation Drug Index aim to refine the indices by removing companies primarily involved in the CXO (Contract Research Organization, Contract Manufacturing Organization, and Contract Development and Manufacturing Organization) sector, thereby better reflecting the trends in the innovative drug industry [1][2][3]. Index Adjustments - The Hang Seng Innovation Drug Index has reduced its constituent stocks from 36 to 29 by removing 7 companies, while the Hang Seng Hong Kong Stock Connect Innovation Drug Index has decreased from 34 to 29 by excluding 5 companies [1][3]. - The removed CXO companies previously accounted for approximately 20% of the weight in the Hang Seng Hong Kong Stock Connect Innovation Drug Index, which is expected to enhance the index's ability to reflect the development trends of the innovative drug industry [1][2]. Performance Metrics - Historical data shows that the revised index has improved its performance, with the annualized return increasing from 3.2% to 8.2% for 2023, and from -11.5% to -4.5% for 2024 [4]. - The Hang Seng Innovation Drug Index is projected to achieve its first annual increase since 2020, with a year-to-date increase of 116% as of August 22, 2025, outperforming the broader market and the healthcare sector [4]. CXO Sector Insights - The removal of CXO companies, particularly those from the WuXi AppTec group, may lead to short-term capital outflows but could be offset by long-term industry recovery trends and strategic adjustments by the companies [5][6]. - Despite being removed from the indices, several CXO companies reported strong performance in the first half of the year, with WuXi Biologics achieving a revenue of 9.95 billion yuan, a year-on-year increase of 16.1% [5]. Future Outlook - Analysts suggest that the CXO sector is poised for recovery, driven by the increasing demand for clinical trial services and the strategic direction of domestic innovative drug companies [6]. - The CXO industry is expected to benefit from the competitive advantages of being a major production country, alongside a favorable regulatory environment and the rising complexity of new drug development [6].

Investment Rating - The report maintains a strong buy rating for the pharmaceutical sector, indicating a bullish outlook for the industry [3]. Core Insights - The pharmaceutical sector is expected to experience a broad rally, driven by innovative drugs leading the charge. The sector index showed a notable upward trend in the first half of 2025, particularly in April, with a valuation premium of 275.19%, significantly above historical averages [4][18]. - Public funds are increasingly favoring pharmaceutical stocks, particularly in innovative drugs and medical devices, supported by stable growth in basic medical insurance funds [4][22]. Section Summaries 1. Market Performance - The pharmaceutical sector has shown a strong upward trend since Q3 2024, outperforming the broader market indices. The sector index rose by 24.51% from the beginning of 2025 to August 29, 2025, surpassing the Shanghai and Shenzhen 300 index by 11.07 percentage points [11][12]. - Medical services and chemical raw materials have performed particularly well, with medical services up by 80.24% and chemical raw materials up by 53.67% as of August 28, 2025 [17]. 2. Industry Overview - The pharmaceutical manufacturing industry has shown resilience, with stable revenue growth and a healthy operating environment for basic medical insurance funds. The overall revenue of the pharmaceutical manufacturing industry has experienced fluctuations but is on a recovery path [31][35]. - The innovative drug business development (BD) has seen explosive growth, with China becoming a hotspot for multinational corporations (MNCs) seeking partnerships. The total transaction amount for BD in 2024 reached a record high of $640.8 billion, with significant contributions from overseas transactions [36][38]. 3. Subsector Analysis - Innovative drugs are leading the growth, with 21 A-share innovative drug companies reporting a revenue of 28.69 billion yuan in the first half of 2025, a year-on-year increase of 42%. The net profit loss has narrowed significantly, indicating a positive trend in profitability [56]. - The medical device sector is also expected to see a turning point in the second half of 2025, with a 62.75% year-on-year growth in the overall bidding market for medical devices in the first half of 2025, exceeding 80 billion yuan [52].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown rapid growth in clinical business and possesses a rich reserve of innovative assets [1] - In H1 2025, the company achieved operating revenue of 590 million yuan, a year-on-year increase of 4.87%, while the net profit attributable to the parent company was 130 million yuan, a year-on-year decrease of 12.61% [4][5] - The second quarter of 2025 saw revenue of 359 million yuan, a year-on-year increase of 15.73%, and a net profit of 101 million yuan, a year-on-year increase of 32.23% [4] Summary by Sections Clinical Business and R&D - The company has invested continuously in R&D, with over twenty types of proprietary Class 1 new drugs in the pipeline, covering various important therapeutic areas [5][6] - Key projects include: 1. STC007 injection for postoperative pain and chronic kidney disease-related itching, with ongoing clinical trials [5] 2. STC008 injection targeting cachexia in advanced solid tumors, with all healthy subjects recruited for Phase Ia trials [5] 3. ZM001 injection, a CAR-T cell therapy for moderate to severe SLE, currently in Phase I trials [5] 4. IC19, a universal CAR-T targeting CD19, in the IIT stage [6] Financial Performance - In H1 2025, the company’s pharmaceutical research revenue was 203 million yuan (down 40.80%), while clinical trials and bioanalysis revenue was 279 million yuan (up 29.05%) [7] - The company expects revenue for 2025-2027 to be 1.306 billion, 1.587 billion, and 1.841 billion yuan, respectively, with year-on-year growth rates of 21.1%, 21.5%, and 16.0% [8] - The net profit attributable to the parent company is projected to be 236 million, 307 million, and 345 million yuan for the same period, with growth rates of 32.8%, 30.3%, and 12.4% [8] Market Position and Future Outlook - The company is expected to continue increasing the number of proprietary products approved for market, which will enhance revenue post-R&D phase [7] - The company maintains a strong focus on innovation and expanding its clinical business, which is expected to contribute significantly to future growth [5][7]

Group 1 - The pharmaceutical sector is experiencing positive developments, with a joint initiative from the National Health Commission and other departments aiming to enhance ear and hearing health services by 2030, targeting a coverage of over 90% in prefecture-level cities [1] - The medical device industry is expected to benefit from policy support, particularly in AI and imaging/surgical applications, with significant potential for domestic equipment replacement [1] - The impact of centralized procurement on the medical consumables sector is gradually diminishing, leading to a potential recovery in high-value consumables [1] Group 2 - The innovative drug sector is showing positive performance driven by policy and funding, with expectations for overseas business development and clinical data to catalyze industry upgrades [1] - The Chinese herbal medicine sector is nearing the end of inventory clearance, with attention on beneficiaries of innovation-driven and centralized procurement policies [1] - The CXO sector is seeing improvements in fundamentals, with orders increasing quarterly as the industry enters an upward cycle [1] Group 3 - China's innovative drugs are entering a phase of realization of results, with numerous research and development advancements that are not affected by trade frictions, expected to remain a key investment theme in the pharmaceutical sector through 2025 [1] - The Guotai Innovation Drug ETF (589720) focuses on innovative drug companies in the Sci-Tech Innovation Board, tracking an index of 30 representative high-quality companies, primarily in high-growth biotech, with a 20% limit on daily price fluctuations to better align with sector volatility [1][2] Group 4 - Since the "924 market" rally last year, the Sci-Tech Innovation Drug Index has outperformed major Hong Kong innovation drug indices, with respective gains of 75%, 70%, and 70% during the market rebound from September 24, 2024, to June 30, 2025 [2] - The Sci-Tech Innovation Drug Index may help capture better returns when market risk appetite increases [2]

Core Viewpoint - The global drug development model has fundamentally shifted from a "solo" approach to a collaborative one, with the rise of the CXO industry accelerating new drug development processes [1] Group 1: CRDMO Model - WuXi AppTec's CRDMO model integrates the entire drug development process from research (R) to development (D) and commercialization (M), allowing the company to capture industry innovation trends and provide downstream business support [2] - The CRDMO model has enabled WuXi AppTec to establish partnerships with over 150 companies in the targeted protein degradation (TPD) field, synthesizing more than 188,000 complex TPD compounds, with over 70 entering preclinical stages and more than 10 in late-stage development [2] Group 2: Operational Efficiency - The integrated CRDMO model facilitates seamless collaboration among multiple teams, reducing costs and project transfer risks, thus enhancing the efficiency of new drug development [3] - WuXi AppTec has expanded its global footprint from a single 650-square-meter lab to nearly 30 R&D and production bases worldwide, optimizing facility utilization and lowering investment costs and risks [4] Group 3: Financial Performance - WuXi TIDES reported a revenue of 5.03 billion yuan in the first half of 2025, reflecting a year-on-year growth of 141.6%, making it one of the fastest-growing segments for WuXi AppTec [5] - The company is also expanding its small molecule production capacity, with projections indicating that the total reactor volume at its Changzhou and Taixing facilities will exceed 4 million liters by the end of 2025 [5] Group 4: Quality and Compliance - WuXi AppTec's global operations adhere to high-quality standards, as evidenced by its two API production bases in Changzhou and Taixing passing FDA inspections without any non-compliance issues [6] Group 5: Workforce and Culture - The company has grown its team from 100 process chemists to over 3,000, enhancing its ability to meet diverse client needs without delays [7] - WuXi AppTec emphasizes its commitment to supporting drug discovery, development, and production, aiming to benefit the industry, clients, and ultimately patients [7]

Market Overview - On September 1, the Hong Kong stock market opened strongly, with the Hang Seng Index rising by 539 points or 2.2% to close at 25,617 points, driven by Alibaba's (9988 HK) performance [1] - The Hang Seng Tech Index also increased by 2.2%, closing at 5,798 points, with total market turnover exceeding 380.2 billion HKD and net inflow from the Stock Connect reaching 11.94 billion HKD [1] - Despite the overall rise, market breadth showed adjustments, with funds concentrating on technology, biomedicine, and non-ferrous metal stocks [1] Sector Performance - Alibaba's stock surged by 18.5% in a single day, marking the strongest increase among blue-chip stocks, with a trading volume of 54.92 billion HKD, the highest since its listing [1] - Semiconductor stocks also performed well, with SMIC (981 HK) rising by 4.9% due to increased capital expenditure in AI [1] - Biomedicine and non-ferrous metal stocks continued their strong performance, with Zijin Mining (2899 HK), Zhaojin Mining (1818 HK), and Luoyang Molybdenum (3993 HK) rising between 6.7% and 8.9% [1] Economic Indicators - The overall sentiment in the Hong Kong stock market remains stable, with active trading focused on high-performing stocks, indicating a structural market trend [2] - In August, China's official manufacturing PMI showed a slight recovery but remained in contraction territory, highlighting weak internal and external demand [2] - The non-manufacturing PMI also saw a minor increase, but the internal structure showed divergence, with the construction sector weakening and the service sector rebounding [2] Real Estate Dynamics - New home transaction volumes in major cities showed a year-on-year increase of 3.6% to 1.8 million square meters for the week ending August 31, indicating a recovery compared to the previous week [3] - Performance varied across city tiers, with first-tier cities seeing a decline of 5.1%, while second-tier cities experienced a growth of 17.7% [3] Automotive Sector Insights - The automotive sector lagged behind technology stocks, with BYD (1211 HK) reporting a net profit of 6.4 billion RMB for Q2, down 30% year-on-year and 31% quarter-on-quarter, below expectations [4] - Intense price competition has compressed profit margins, with a gross margin of 16.3% in Q2, down 3.8 percentage points [4] - The market is focused on BYD's overseas expansion, with production capacity in Indonesia, Brazil, and Hungary expected to be completed ahead of schedule [4] Healthcare Sector Developments - The Hang Seng Healthcare Index surged by 4.9%, led by innovative drugs and the CXO sector [4] - Most leading innovative drug companies reported strong interim results, while traditional pharmaceutical and medical device sectors continue to be affected by centralized procurement policies [4] Renewable Energy and Utilities - Recent performance in the renewable energy and utilities sector was mixed, with nuclear, gas, and environmental sectors generally declining, while solar and thermal power sectors saw gains [5] - Xinyi Solar (968 HK), Flat Glass (6865 HK), and GCL-Poly Energy (3800 HK) saw increases of 0.9%, 1.3%, and 2.4% respectively [5] Company-Specific Analysis: Innovent Biologics (1801 HK) - Innovent Biologics reported a 50.6% year-on-year increase in revenue to 5.95 billion RMB for the first half of the year, with a gross profit increase of 56.3% to 5.12 billion RMB [6] - The company successfully turned a profit with a net income of 830 million RMB, compared to a loss of 390 million RMB in the same period last year [6] - The main product, the oncology drug Darbepoetin, saw a 16% increase in sales revenue to approximately 2.7 billion USD (about 19.6 billion RMB) [6] Future Projections for Innovent Biologics - Sales revenue is expected to grow rapidly from 2025 to 2027, driven by the anticipated approval of new indications for existing products and the launch of new drugs [7] - The company plans to increase R&D investment, projecting over 300 million USD for the year, with expectations for net profit to significantly exceed previous forecasts [7] - Long-term prospects for pipeline products IBI363 and IBI343 are promising, with ongoing clinical trials showing positive results [8] Target Price and Rating Adjustments for Innovent Biologics - The target price for Innovent Biologics has been raised to 113.75 HKD, with a rating upgrade to "Buy" based on revised revenue forecasts and profit expectations [9]

Group 1: Market Overview - On September 1st, the Hong Kong stock market started well, with the Hang Seng Index rising 539 points or 2.2% to close at 25,617 points, and the Hang Seng Tech Index rising 2.2% to close at 5,798 points. The market turnover reached over HK$380.2 billion, and the Hong Kong Stock Connect had a net inflow of HK$11.94 billion [1] - The overall sentiment of the Hong Kong stock market remained stable, with active trading. The market presented a structural trend, mainly trading around high - performance stocks. The Hong Kong stock market is likely to continue to fluctuate at a high level. It is recommended to focus on technology leaders with high performance certainty, semiconductor, AI and computing infrastructure, and cyclical sectors such as non - ferrous metals [2] Group 2: Macro - dynamics - In the real estate sector, the volume of new home sales in 30 large and medium - sized cities reached 1.8 million square meters last week (as of August 31st), a year - on - year increase of 3.6%, better than the 9.2% year - on - year decline in the previous week, and a month - on - month increase of 11.6%, worse than the 26.2% month - on - month decline in the previous week. The year - on - year performance of different types of cities was divergent [3] Group 3: Industry Dynamics Automobile - In the automobile sector, BYD's second - quarter net profit was RMB 6.4 billion, a year - on - year decrease of 30% and a month - on - month decrease of 31%, lower than expected. The gross profit margin in the second quarter was 16.3%, a month - on - month decrease of 3.8 percentage points. The market has lowered its target price, and the stock price fell 5.2% on Monday to a three - month low. The market is focusing on the company's overseas expansion progress [4] Healthcare - The Hang Seng Healthcare Index rose 4.9% yesterday, led by the innovative drug and CXO sectors. The performance of innovative drug leading enterprises was mostly excellent, the CXO sector was recovering, while the traditional pharmaceutical and traditional medical device sectors were still affected by centralized procurement, and the performance of the medical service sector was still affected by medical insurance cost control [4] New Energy and Utilities - The performance of new energy and utility stocks in Hong Kong was divergent. The photovoltaic, thermal power, and Hong Kong utility sectors generally rose, while the nuclear power, gas, and environmental protection sectors generally fell [5] Group 4: Research Report on Xinda Bio - pharm (1801 HK) - In the first half of 2025, Xinda Bio - pharm's performance greatly exceeded expectations. The company's revenue in the first half of the year increased by 50.6% year - on - year to RMB 5.95 billion, and the gross profit increased by 56.3% year - on - year to RMB 5.12 billion, successfully turning losses into profits [6] - It is expected that the company's product sales revenue will grow rapidly from 2025 - 2027E. The profit in the second half of the year is expected to be significantly lower than that in the first half but still greatly exceed expectations. The net profit of shareholders from 2026 - 2027E is also expected to exceed expectations [7] - In the long run, in - research products such as IBI363 and IBI343 are expected to bring new highlights. As of the end of June, the company had 21 in - research products [8] - The target price is raised to HK$113.75, and the rating is upgraded to "Buy" [9] Group 5: Research Report on GUOQUAN FOOD (2517 HK) - GUOQUAN FOOD is China's dominant one - stop provider of at - home meal solutions. By the end of 2024, the number of its retail stores reached 10,150, leading the nearly RMB 400 billion market with a 3% share [10] - After the restructuring of the sales network, the number of stores has stabilized at over 10,000, and it is expected to have a net increase of 780 stores in 2025. The future strategy will prioritize lower - tier markets for expansion [11] - The company has built a strong supply chain moat, pioneering a 'single product, single factory' upstream supply chain cooperation model [12] - The report initiates coverage with a "Buy" rating and a target price of HK$5.17, forecasting a revenue CAGR of 22.2% from 2025 to 2027E [13]

Core Viewpoint - The biopharmaceutical sector is experiencing significant growth, with the Biopharmaceutical ETF (159839) reaching new highs and individual stocks like Changchun High-tech (000661) and Rongchang Bio (688331) showing strong performance [1][4]. Group 1: ETF Performance - The Biopharmaceutical ETF (159839) increased by 3.18%, reaching a record high since its launch [1]. - Over the past week, the ETF has seen a cumulative increase of 0.99% [1]. - The ETF's trading volume was 5.11%, with a total transaction value of 31.17 million yuan [1]. Group 2: Fund Flows - The ETF experienced a net outflow of 12.21 million yuan recently, but over the last ten trading days, there were net inflows on seven days, totaling 22.71 million yuan [3]. - The ETF's scale grew by 3.96 million yuan in the past week, ranking it in the top third among comparable funds [3]. Group 3: Company Insights - Changchun High-tech reported a revenue of 6.603 billion yuan for the first half of 2025, a slight decrease of 0.54% year-on-year, with a net profit of 983 million yuan, down 42.85% [4]. - The company is shifting from a single product focus to a diversified strategy, with increased R&D investment of 1.335 billion yuan, up 17.32% year-on-year [4]. - The company is advancing multiple innovative projects in key therapeutic areas, including oncology and immunology [4]. Group 4: Industry Trends - The overall pharmaceutical industry is seeing a slowdown in revenue and profit growth, but the CXO and innovative drug sectors are performing well, with CXO revenue up 14.16% and net profit up 64.03% in the first half of 2025 [5]. - The innovative drug sector is experiencing high growth in product revenue and licensing deals, indicating a positive trend for the industry [5]. - There is a recommendation to focus on leading CXO companies and innovative drug firms with significant market potential [5].